• Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Nektar Therapeutics

+ Add to Watchlist

ITH:GR

10.560 EUR 0.050 0.48%

As of 02:15:08 ET on 09/19/2014.

Snapshot for Nektar Therapeutics (ITH)

Open: 10.259 Day's Range: 10.259 - 10.560 Volume: 0
Previous Close: 10.510 52wk Range: 6.619 - 11.810 1-Yr Rtn: +4.87%

Stock Chart for ITH

No chart data available.
  • ITH:GR 10.560
  • 1D
  • 1M
  • 1Y
10.510
Interactive ITH Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for ITH

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. DAX -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (12/2014) -0.6330
Est. PEG Ratio -
Market Cap (M EUR) 1,344.31
Shares Outstanding (M) 127.30
30 Day Average Volume 155
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 11/07/2014
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for ITH

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for ITH

Nektar Therapeutics is a clinical-stage biopharmaceutical company which develops a pipeline of drug candidates that utilize company platforms. The Company's product pipeline is comprised of early to late stage drug candidates across a number of therapeutic areas including oncology, pain, anti-infectives, anti-viral and immunology.

Howard W RobinPresident/CEOJohn L NicholsonSenior VP/CFO
Stephen K DobersteinSenior VP/Chief Scientific OfcrGil M LabrucherieSenior VP/Secy/Gen Counsel
More Company Profile & Key Executives for ITH

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil